Company intelligence / Profile preview

Lian Cardiovascular

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Lian Cardiovascular is a specialized therapeutic division of LianBio, focused on developing and commercializing innovative cardiovascular therapies for the Greater China market and other Asian territories. The company's lead program is mavacamten, a first-in-class cardiac myosin inhibitor licensed from Bristol Myers Squibb (formerly MyoKardia) for the treatment of hypertrophic cardiomyopathy. Lian Cardiovascular leverages a cross-border model to bridge global biopharmaceutical innovation with the significant unmet medical needs in China. Its pipeline also includes danicamtiv, a cardiac myosin activator aimed at treating heart failure with reduced ejection fraction.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Bristol Myers SquibbMyoKardia

Beyond the preview

Go deeper on Lian Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lian Cardiovascular.

Explore the full profile